<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7457578\results\search\disease\results.xml">
  <result pre="and Practice Regarding COVID-19 among Patients with Musculoskeletal and Rheumatic" exact="Diseases" post="in Nepal: A Web-Based Cross-Sectional Study Vaidya et al"/>
  <result pre="(https://www.dovepress.com/terms.php). Abstract Purpose The global health crisis created by coronavirus" exact="disease" post="in 2019, ie, COVID-19, is of serious concern to"/>
  <result pre="COVID-19, is of serious concern to rheumatologists. The relationship of" exact="rheumatic" post="diseases, their therapies, and COVID-19 with multiple genuine and"/>
  <result pre="information available online can influence the knowledge and attitudes of" exact="rheumatic" post="patients. This Google Forms study was conducted to understand"/>
  <result pre="Methods A web-based cross-sectional study was conducted among patients with" exact="rheumatic" post="diseases. A modified version of a questionnaire was used"/>
  <result pre="translated into Nepali for comprehensibility. The final questionnaire contained a" exact="total" post="of 29 questions: six on demographic parameters and twelve,"/>
  <result pre="twelve, five, and six on knowledge, attitudes and practice, respectively." exact="Simple" post="descriptive statistics were used to describe the positive responses"/>
  <result pre="others, and 18.9% believed that antirheumatic medications could increase their" exact="susceptibility to" post="infection. A majority (&amp;gt;94.7%) of them practiced preventive measures."/>
  <result pre="majority (&amp;gt;94.7%) of them practiced preventive measures. Conclusion Patients with" exact="rheumatic" post="diseases were aware of the general clinical features, routes"/>
  <result pre="Keywords SARS-CoV-2 coronavirus KAP survey fig-count: table-count: ref-count: page-count: Introduction" exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) belongs to the"/>
  <result pre="SARS-CoV-2 coronavirus KAP survey fig-count: table-count: ref-count: page-count: Introduction Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) belongs to the coronavirus"/>
  <result pre="coronavirus KAP survey fig-count: table-count: ref-count: page-count: Introduction Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) belongs to the coronavirus family"/>
  <result pre="KAP survey fig-count: table-count: ref-count: page-count: Introduction Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) belongs to the coronavirus family responsible"/>
  <result pre="to the coronavirus family responsible for the 2019 pandemic coronavirus" exact="disease" post="19 (COVID-19), which was first identified in Wuhan, China"/>
  <result pre="further compounds this effect.4 After the first report of SARS-CoV-2" exact="infection" post="from Nepal in a student who returned from Wuhan,5"/>
  <result pre="survey questionnaire to understand the knowledge, attitudes, and practices of" exact="rheumatic" post="patients regarding COVID-19 in Nepal during the first week"/>
  <result pre="April 2020. Study Population Patients with various rheumatologic diseases (eg," exact="rheumatoid arthritis," post="systemic lupus erythematosus, fibromyalgia, osteoarthritis, and gout) were selected"/>
  <result pre="Study Population Patients with various rheumatologic diseases (eg, rheumatoid arthritis," exact="systemic" post="lupus erythematosus, fibromyalgia, osteoarthritis, and gout) were selected randomly"/>
  <result pre="Population Patients with various rheumatologic diseases (eg, rheumatoid arthritis, systemic" exact="lupus erythematosus," post="fibromyalgia, osteoarthritis, and gout) were selected randomly from the"/>
  <result pre="from the patient registry of the National Centre for Rheumatic" exact="Diseases" post="(NCRD), Kathmandu, Nepal, comprising a total of around 22,000"/>
  <result pre="National Centre for Rheumatic Diseases (NCRD), Kathmandu, Nepal, comprising a" exact="total" post="of around 22,000 patients. A sample of 384 patients"/>
  <result pre="patients was calculated with an estimated 3 million population with" exact="rheumatic" post="diseases where the margin of error was 5%. Considering"/>
  <result pre="to use the same questions with modification in terms of" exact="rheumatic" post="patients obtained. The modified questionnaire was translated into the"/>
  <result pre="version was distributed to the study population. It contained a" exact="total" post="of 29 questions: six pertaining to demographic parameters, including"/>
  <result pre="of 29 questions: six pertaining to demographic parameters, including the" exact="rheumatic" post="disease they were suffering from, twelve to knowledge about"/>
  <result pre="29 questions: six pertaining to demographic parameters, including the rheumatic" exact="disease" post="they were suffering from, twelve to knowledge about the"/>
  <result pre="Diseses (NCRD). Statistical Analysis All responses were qualitative in nature." exact="Simple" post="descriptive statistics were used to describe the positive responses"/>
  <result pre="of the questionnaire was satisfactory, with Cronbachâ€™s Î±=0.769. Survey A" exact="total" post="of 380 patients participated in the survey, the majority"/>
  <result pre="survey, the majority being females (63.2%). Around 132 (34.7%) had" exact="rheumatoid arthritis," post="68 (17.9%) had connective tissue disease, and 40 (10.5%)"/>
  <result pre="(63.2%). Around 132 (34.7%) had rheumatoid arthritis, 68 (17.9%) had" exact="connective tissue disease," post="and 40 (10.5%) had spondyloarthropathy requiring treatment with either"/>
  <result pre="68 (17.9%) had connective tissue disease, and 40 (10.5%) had" exact="spondyloarthropathy" post="requiring treatment with either disease-modifying antirheumatic drugs (DMARDs) or"/>
  <result pre="DMARDsImmunosuppressant therapyBiological agentsOthers 192 (50.5)84 (22.2)84 (22.2)20 (5.1) Abbreviations: SEE," exact="secondary" post="education examination; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus;"/>
  <result pre="(50.5)84 (22.2)84 (22.2)20 (5.1) Abbreviations: SEE, secondary education examination; RA," exact="rheumatoid arthritis;" post="SLE, systemic lupus erythematosus; SPA, spondyloarthritis; DMARDs, disease-modifying antirheumatic"/>
  <result pre="(5.1) Abbreviations: SEE, secondary education examination; RA, rheumatoid arthritis; SLE," exact="systemic" post="lupus erythematosus; SPA, spondyloarthritis; DMARDs, disease-modifying antirheumatic drugs. Knowledge"/>
  <result pre="Abbreviations: SEE, secondary education examination; RA, rheumatoid arthritis; SLE, systemic" exact="lupus erythematosus;" post="SPA, spondyloarthritis; DMARDs, disease-modifying antirheumatic drugs. Knowledge Domain Most"/>
  <result pre="in patients with comorbidities. Knowledge results for participants regarding COVID-19" exact="infection" post="is given in Table 2, and was acceptable for"/>
  <result pre="sure 348 (91.6)8 (2.1)6.3 Unlike the common cold, stuffy nose," exact="runny nose," post="and sneezing are less common in persons infected with"/>
  <result pre="There is currently no effective cure for COVID-19, but early" exact="symptomatic" post="and supportive treatment can help most patients recover from"/>
  <result pre="develop to severe cases. Only those who are elderly, have" exact="chronic" post="illnesses, and are obese are likely to have severe"/>
  <result pre="Eating meat or being in contact animals will result in" exact="infection" post="by the COVID-19 virus. YesNoNot sure 64 (16.9)168 (44.2)148"/>
  <result pre="sure 16 (4.2)320 (84.2)44 (11.6) The COVID-19 virus spreads via" exact="respiratory" post="droplets of infected individuals. YesNoNot sure 352 (92.6)16 (4.2)12"/>
  <result pre="(3.2) Ordinary residents can wear general medical masks to prevent" exact="infection" post="by the COVID-19 virus. YesNoNot sure 284 (74.8)60 (15.7)36"/>
  <result pre="for children and young adults to take measures to prevent" exact="infection" post="with the COVID-19 virus. YesNoNot sure 36 (9.4)340 (89.5)4"/>
  <result pre="COVID-19 virus. YesNoNot sure 36 (9.4)340 (89.5)4 (1.1) To prevent" exact="infection" post="with COVID-19, individuals should avoid going to crowded places"/>
  <result pre="that the antirheumatic medications they were taking could increase their" exact="susceptibility to" post="infection. Responses on the attitude domain are given in"/>
  <result pre="you think that you have more chance of getting the" exact="infection" post="because of your rheumatic disease? YesNoNot sure 120 (31.5)104"/>
  <result pre="have more chance of getting the infection because of your" exact="rheumatic" post="disease? YesNoNot sure 120 (31.5)104 (27.3)176 (46.3) Do you"/>
  <result pre="you think that you have more chance of getting the" exact="infection" post="because of your medicines? YesNoNot sure 72 (18.9)156 (41.1)152"/>
  <result pre="(38.9)180 (47.4) Do you think that vaccination against flu or" exact="pneumonia" post="can have protective effect against COVID-19 for you? YesNoNot"/>
  <result pre="their own and few admitted stopping medication for fear of" exact="infection" post="(4.2%) or unavailability of medicine due to lockdown (8.4%)."/>
  <result pre="no difference in attitude or practice changes between higher and" exact="lower" post="education (p=0.969 and 0.643, respectively). Also, no difference was"/>
  <result pre="DMARDs and immunosuppressants in knowledge of symptoms (p=0.196), risk of" exact="infection" post="(p=0.607), or change in dose or discontinuation of medication"/>
  <result pre="stopped any medicines you are taking fearing the risk of" exact="infection" post="with COVID-19? YesNo 16 (4.2)364 (95.8) Have you discontinued"/>
  <result pre="32 (8.4)348 (91.6) Have you taken vaccination for flu or" exact="pneumonia" post="with fear of COVID-19? YesNo 12 (3.1)368 (96.9) Discussion"/>
  <result pre="study found an acceptable level of knowledge among patients with" exact="rheumatic" post="diseases regarding the symptoms of COVID-19 infection and measures"/>
  <result pre="among patients with rheumatic diseases regarding the symptoms of COVID-19" exact="infection" post="and measures required for prevention of transmission. Since the"/>
  <result pre="responses in the domains of knowledge and attitude.11,12 There are" exact="limited" post="sources of information regarding the risks of infection due"/>
  <result pre="There are limited sources of information regarding the risks of" exact="infection" post="due to rheumatic disease and severity of illness. Any"/>
  <result pre="sources of information regarding the risks of infection due to" exact="rheumatic" post="disease and severity of illness. Any viral infection can"/>
  <result pre="of information regarding the risks of infection due to rheumatic" exact="disease" post="and severity of illness. Any viral infection can have"/>
  <result pre="infection due to rheumatic disease and severity of illness. Any" exact="viral infection" post="can have an aggressive course leading to severe disease"/>
  <result pre="due to rheumatic disease and severity of illness. Any viral" exact="infection" post="can have an aggressive course leading to severe disease"/>
  <result pre="viral infection can have an aggressive course leading to severe" exact="disease" post="manifestations and respiratory complications in immunocompromised patients. The true"/>
  <result pre="have an aggressive course leading to severe disease manifestations and" exact="respiratory" post="complications in immunocompromised patients. The true incidence of COVID-19"/>
  <result pre="immunocompromised patients. The true incidence of COVID-19 in patients with" exact="rheumatic" post="disease has been reported not to be much higher"/>
  <result pre="patients. The true incidence of COVID-19 in patients with rheumatic" exact="disease" post="has been reported not to be much higher than"/>
  <result pre="is not much different, with very few cases of severe" exact="disease" post="reported in patients receiving biological or target-specific agents. These"/>
  <result pre="also shows a level of uncertainty in our patients with" exact="rheumatic" post="disease, with around a third of patients responding that"/>
  <result pre="that they felt that they were at increased risk of" exact="infection" post="with SARS-CoV-2 due to their disease. A few patients"/>
  <result pre="a reduction or withdrawal might be considered in those with" exact="symptomatic" post="infections only. Some commonly used drugs like hydroxychloroquine might"/>
  <result pre="reduction or withdrawal might be considered in those with symptomatic" exact="infections" post="only. Some commonly used drugs like hydroxychloroquine might have"/>
  <result pre="glycosylation of cellular receptors and increasing endosomal pH required for" exact="viral" post="fusion.14 Some guidelines have recommended hydroxychloroquineâ€™s use for prophylaxis"/>
  <result pre="might be zero protective role of hydroxychloroquine, as 25% of" exact="rheumatic" post="patients using this drug had concomitant COVID-19 infections.15 In"/>
  <result pre="might have protective actions in COVID-19 infection.16 Routine vaccination against" exact="pneumonia" post="and flu is recommended before initiation of any DMARDs."/>
  <result pre="regarding general symptoms, transmission, and preventive measures in patients with" exact="rheumatic" post="disease should be considered acceptable. However, the findings of"/>
  <result pre="general symptoms, transmission, and preventive measures in patients with rheumatic" exact="disease" post="should be considered acceptable. However, the findings of this"/>
  <result pre="survey highlight caveats in certain aspects of knowledge of our" exact="rheumatic" post="patients, and it would thus be helpful to design"/>
  <result pre="of great importance for the control and prevention of the" exact="disease" post="outbreak.17 Conclusion Patients with rheumatic diseases were aware of"/>
  <result pre="control and prevention of the disease outbreak.17 Conclusion Patients with" exact="rheumatic" post="diseases were aware of the general clinical features, route"/>
  <result pre="from the review board of the National Center for Rheumatic" exact="Diseases" post="(NCRD). Disclosure The authors report no conflicts of interest"/>
  <result pre="in this work. References References 1.collab: WHO. Naming the coronavirus" exact="disease" post="(COVID-19) and the virus that causes it: World Health"/>
  <result pre="[Internet]; 2020Available from: https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/. Accessed 810, 2020. 3.collab: WHO. Coronavirus" exact="disease" post="(COVID-19) outbreak situation. Available from: https://www.who.int/docs/defaultsource/coronaviruse/situationreports/20200409-sitrep-80-covid-19.pdf?sfvrsn=1b685d64_2. 4.WisemanAC. Immunosuppressive medications."/>
  <result pre="2020. 13.TamL-S, TanakaY, HandaR, et al. Care for patients with" exact="rheumatic" post="diseases during COVID-19 pandemic: a position statement from APLAR."/>
  <result pre="safety and efficacy of tocilizumab in patients with severe COVID-19" exact="pneumonia" post="(COVACTA); 2020Available from: https://clinicaltrials.gov/ct2/show/NCT04320615. Accessed 810, 2020. 17.PapachristodoulouE, KakoullisL,"/>
 </snippets>
</snippetsTree>
